Evaluation Of Efficacy of Lanthanum Carbonate in Rats with Chronic Kidney Disease
Fuente:
Zenodo
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Recurso digital |
| Publié: |
Zenodo
2025
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1866901246855610368 |
|---|---|
| author | S. S. Jadhav1, Dr. S. M. Ghadigaonkar*2, M. G. Ghadigaonkar3 |
| author_facet | S. S. Jadhav1, Dr. S. M. Ghadigaonkar*2, M. G. Ghadigaonkar3 |
| contents | <p><span>Lanthanum carbonate (Vetricare Renal (®), Vetrina Healthcare Pvt Ltd) is an effective non-calcium, non-resin phosphate binder for the treatment of hyperphosphataemia in chronic kidney disease (CKD). In this study, we used a rat model of chronic renal failure (CRF) to examine the effects of controlling serum phosphorus with lanthanum carbonate treatment on the biochemical and bone abnormalities.<span> </span>Rats were randomly divided into 7 groups (n=10). Chronic Kidney Disease was induced by Adenine @220 mg/kg/day orally for 14 days. Groups IV–VII received Lanthanum Carbonate at varying doses (150–750 mg/kg/day) from day 15 to 42. Adenine administration significantly reduced body weight, with values dropping from 172.5 ± 2.007 g on day 0 to 158 ± 2.494<span> </span>on day 14. However, Lanthanum Carbonate treatment led to a marked improvement in body weight by day 42, particularly in groups receiving 500 mg/kg and 750 mg/kg doses. Adenine also caused a notable increase in serum phosphorus levels (18.36 ± 0.837 mg/dL on day 14 and 17.84 ± 0.811 mg/dL on day 42). Treatment with Lanthanum Carbonate significantly reduced biochemical markers such as Serum Phosphorus, Creatinine, Blood Urea Nitrogen and Alkaline Phosphatase. The higher doses (500 mg/kg and 750 mg/kg) were more effective than lower doses (150 mg/kg and 250 mg/kg). No significant changes were observed in serum calcium, Serum Glutamate Pyruvate Transaminase or Serum Glutamate Oxaloacetate Transaminase levels. Histopathological examination confirmed renal protection, while histomorphometry analysis indicated an osteoprotective effect. Treatment with lanthanum carbonate reduced the biochemical and bone abnormalities in a rat model of CRF. These findings suggest that Lanthanum Carbonate, particularly at higher doses, offers significant renal and skeletal protection in Chronic Kidney Disease induced by Adenine in rats.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_15621357 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Evaluation Of Efficacy of Lanthanum Carbonate in Rats with Chronic Kidney Disease S. S. Jadhav1, Dr. S. M. Ghadigaonkar*2, M. G. Ghadigaonkar3 Lanthanum Carbonate, Chronic Kidney Disease, Adenine, Interleukin-1β, Caspase-3, Histopathology, Histomorphometry, Vetricare Renal <p><span>Lanthanum carbonate (Vetricare Renal (®), Vetrina Healthcare Pvt Ltd) is an effective non-calcium, non-resin phosphate binder for the treatment of hyperphosphataemia in chronic kidney disease (CKD). In this study, we used a rat model of chronic renal failure (CRF) to examine the effects of controlling serum phosphorus with lanthanum carbonate treatment on the biochemical and bone abnormalities.<span> </span>Rats were randomly divided into 7 groups (n=10). Chronic Kidney Disease was induced by Adenine @220 mg/kg/day orally for 14 days. Groups IV–VII received Lanthanum Carbonate at varying doses (150–750 mg/kg/day) from day 15 to 42. Adenine administration significantly reduced body weight, with values dropping from 172.5 ± 2.007 g on day 0 to 158 ± 2.494<span> </span>on day 14. However, Lanthanum Carbonate treatment led to a marked improvement in body weight by day 42, particularly in groups receiving 500 mg/kg and 750 mg/kg doses. Adenine also caused a notable increase in serum phosphorus levels (18.36 ± 0.837 mg/dL on day 14 and 17.84 ± 0.811 mg/dL on day 42). Treatment with Lanthanum Carbonate significantly reduced biochemical markers such as Serum Phosphorus, Creatinine, Blood Urea Nitrogen and Alkaline Phosphatase. The higher doses (500 mg/kg and 750 mg/kg) were more effective than lower doses (150 mg/kg and 250 mg/kg). No significant changes were observed in serum calcium, Serum Glutamate Pyruvate Transaminase or Serum Glutamate Oxaloacetate Transaminase levels. Histopathological examination confirmed renal protection, while histomorphometry analysis indicated an osteoprotective effect. Treatment with lanthanum carbonate reduced the biochemical and bone abnormalities in a rat model of CRF. These findings suggest that Lanthanum Carbonate, particularly at higher doses, offers significant renal and skeletal protection in Chronic Kidney Disease induced by Adenine in rats.</span></p> |
| title | Evaluation Of Efficacy of Lanthanum Carbonate in Rats with Chronic Kidney Disease |
| topic | Lanthanum Carbonate, Chronic Kidney Disease, Adenine, Interleukin-1β, Caspase-3, Histopathology, Histomorphometry, Vetricare Renal |
| url | https://doi.org/10.5281/zenodo.15621357 |